CytomX Therapeutics

Clinical trials sponsored by CytomX Therapeutics, explained in plain language.

CytomX Therapeutics CTMX NASDAQ

A biotechnology company developing conditionally activated antibody therapeutics for cancer and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 2 Terminated 1

Cancer drug combo study halted after just 3 patients

Disease control Stopped early

This study tested a new drug called CX-072 combined with other cancer treatments for adults with solid tumors or advanced melanoma. The goal was to see if the combination could shrink tumors. However, the study was stopped early and only 3 people took part, so we don't have enoug…

Phase 2 • Sponsor: CytomX Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 08:07 UTC

CytomX Therapeutics

Cancer drug combo study halted after just 3 patients